About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Astrazeneca Pharma India Ltd.
Change Company
BSE Code
506820
ISIN Demat
INE203A01020
Book Value
308.14
NSE Code
ASTRAZEN
Dividend Yield %
0.35
Market Cap
227861.25
P/E
196.87
EPS
46.30
Face Value
2
1 Week
1 Month
3 Months
6 Months
1 Year
30-May-2025
AstraZeneca Pharma gets permission to import for ...
30-May-2025
AstraZeneca Pharma India informs about disclosur...
30-May-2025
AstraZeneca Pharma soars on getting permission to...
29-May-2025
Astrazeneca Pharma India receives approval to imp...
15-Apr-2025
AstraZeneca Pharma surrenders marketing authorisa...
15-Apr-2025
AstraZeneca Pharma India informs about disclosure
05-Apr-2025
AstraZeneca Pharma gets nod to import Osimertinib...
28-Mar-2025
AstraZeneca Pharma India informs about updates
06-Mar-2025
AstraZeneca Pharma India gets nod to import, dist...
04-Mar-2025
AstraZeneca Pharma India gets CDSCO’s nod to impo...
04-Mar-2025
AstraZeneca Pharma India surges on getting CDSCO’...
25-Feb-2025
AstraZeneca Pharma India informs about appointmen...
24-Feb-2025
Astrazeneca Pharma India informs about notice of ...
12-Dec-2024
Astrazeneca Pharma India informs about closure of...
12-Dec-2024
Astrazeneca Pharma India informs about trading wi...
Page
1
of
2
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.